Actelion to axe 135 'mostly R&D' staff, PhII projects possibly up for grabs
This article was originally published in Scrip
Actelion is cutting staff numbers by 135 globally, "the majority in R&D areas", as part of a cost cutting initiative first outlined in May this year. The Swiss firm currently employs around 800 R&D staff. Around 115 of the positions under threat are located in the company's headquarters in Allschwil, Switzerland.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.